Keywords: Novartis, Menveo, Depomed, Abbott, Gralise, USA, FDA, Meningococcal disease, Shingles, Post-herpetic neuralgia

US FDA clears use of Novartis’ Menveo for over two-year-olds; Depomed leaps on approval of shingles drug Gralise

Article | 31 January 2011

Print This

The US Food and Drug Administration has approved Swiss drug major Novartis’ (NOVN: VX) Menveo (meningococcal [Groups A, C, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in